The company said in a 24-week phase 2a study with 16 patients the drug showed "favorable safety, tolerability, and therapeutic effect."
Hereditary hemochromatosis is a genetic disorder that causes the body to absorb too much iron, Protagonist said.
Price: 37.24, Change: +0.14, Percent Change: +0.38